PCI Biotech: Prospectus approved Oslo, December 13, 2016

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
PCI Biotech: Prospectus approved

Oslo, December 13, 2016 - Reference is made to the Stock Exchange Notices published by PCI Biotech Holding ASA («PCI Biotech» or the «Company») on 17 November and 8 December 2016 regarding a guaranteed rights issue of 10 million new shares (the «Rights Issue») at a subscription price of NOK 7 per new share.

The Financial Supervisory Authority of Norway (Nw. "Finanstilsynet") has today approved the prospectus dated 13 December 2016 (the "Prospectus") in connection with the Rights Issue.

The Prospectus will be published electronically tomorrow, 14 December 2016 (at which date the subscription period commences), on the Company's website ( www.pcibiotech.no/share-info/ ) and on the website of the Manager, Fondsfinans AS ( www.beringerfinance.com/deals/#filter=.ongoing ). A paper copy of the prospectus may then also be obtained, free of charge, at PCI Biotech Holding ASA, Ullernchausséen 64, 0379 Oslo and at Fondsfinans AS, Haakon VII's gate 2, 0122 Oslo.

Contact information:     PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo           Ronny Skuggedal, CFO, rs@pcibiotech.no, Mobile: +47 9400 5757

Important Notice The Rights Issue will not be made in any jurisdiction or in any circumstances in which such offer or solicitation would be unlawful. This announcement is not for distribution, directly or indirectly in or into any jurisdiction in which it is unlawful to make any such offer or solicitation to such person or where prior registration or approval is required for that purpose. No steps have been taken or will be taken relating to the Rights Issue in any jurisdiction outside of Norway in which such steps would be required. This publication is not an offer for sale of or the solicitation of an offer to purchase securities in the United States. The Offer Shares and the Subscription Rights have not been registered under the U.S. Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold within the United States.

About PCI Biotech            PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.  PCI is applied to three distinct anticancer paradigms: fima Chem (enhancement of chemotherapeutics for localised treatment of cancer), fima Vacc (T-cell induction technology for therapeutic vaccination), and fima NAc (nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The Company's lead fima Chem programme consists of a Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products.  fima Vacc applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies.   fima NAc utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For more information visit www.pcibiotech.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s Second IND Adds Proof to Its Glue Platform

Updated Category News Views 25

Two IND acceptances from one long-running alliance is not nothing, especially in a drug-discovery business where plenty of polished platform talk never makes it to the clinic. Evotec has cleared that modest but meaningful bar again with Bristol Myers Squibb: a second molecular-glue candidate has received FDA acceptance for an Investigational New Drug application. The...

Continue Reading
Fidelis Puts $140,000 Behind Statewide Postpartum Care

Updated Category News Views 125

A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...

Continue Reading
Miami I20 Tests Appetite for Long-Term U.S. Capital

Updated Category News Views 154

Five days in a Miami airport hotel may not sound like the machinery of national investment policy, yet the guest list for the inaugural I20 Summit is serious enough to make capital markets sit up. From December 11 through 15, the Sovereign Wealth Fund Institute plans to bring sovereign funds, pensions, endowments, family offices, business leaders and U.S....

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 32

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
Weatherford Adds Grant Roach to Its Sports Deal Team

Updated Category News Views 69

Sports investing has reached that awkward middle age where everybody sees the runway, but few can explain exactly where the bumps are. Weatherford Capital’s decision to bring Grant Roach aboard as vice president is not a headline packed with transaction fireworks. It is, however, a pretty clear tell: the Tampa firm intends to put more bodies and more underwriting muscle...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 108

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
Layne’s Jacksonville Debut Tests East Texas Expansion

Updated Category News Views 57

Jacksonville is not some flashy coastal launch, and that is precisely why this Layne’s Chicken Fingers opening matters. A new chicken tender shop at 1217 S. Jackson St. will not move public markets, because this is a franchise-growth story rather than a ticker story. But it does offer a clean look at whether Layne’s can turn its Texas roots into a durable multi-market...

Continue Reading
Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 39

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
CHN Energy's Indonesia Record Deserves a Hard Look

Updated Category News Views 50

Twenty years of boots sinking into swamp mud tells a sturdier story than a polished anniversary slogan. CHN Energy says it entered Indonesia's energy market two decades ago and has since built an operating presence around reliable electricity, local training and community work. In a country scattered across thousands of islands, dependable power is not some decorative...

Continue Reading
Vector's Peptide Pact Needs Proof Before Any Payday

Updated Category News Views 194

A famous orthopedic name can open doors, but it cannot manufacture clinical evidence. That is the plain reality behind Vector Science and Therapeutics' new collaboration with the Andrews Research & Education Foundation. Dr. James Andrews carries enormous credibility in sports medicine, earned across more than five decades of work. For Vector, that association matters. For...

Continue Reading

Top 5 Most Recently Viewed Articles

AMSURG Expands Its Network with Pinnacle Surgery Center Acquisition

Updated Category News Views 950

AMSURG Expands Its Network with Pinnacle Surgery Center Acquisition AMSURG, a prominent independent leader in ambulatory surgery center services, recently achieved a significant milestone by acquiring Pinnacle Surgery Center. This acquisition boosts AMSURG's presence in the healthcare industry, particularly in providing high-quality surgical care to communities. Overview...

Continue Reading
Montauk Renewables Announces Q2 2025 Conference Call Details

Updated Category News Views 192

Montauk Renewables Schedules Q2 2025 Conference Call Montauk Renewables, Inc. (NASDAQ: MNTK), a leading renewable energy company specializing in biogas management, will host its second quarter 2025 conference call on a Thursday morning. This session is set for August 7, 2025, at 8:30 a.m. ET, where they will present their financial results for the period ending June 30,...

Continue Reading
MaxCyte Earnings Report: What Investors Should Know

Updated Category News Views 157

MaxCyte's Earnings Announcement Overview MaxCyte (NASDAQ: MXCT) is gearing up for its quarterly earnings report. Investors are keen to see the results, especially when it comes to their earnings per share (EPS) expectations. Anticipated Earnings Performance Analysts are predicting that MaxCyte will report an EPS of $-0.10. This figure is crucial as it sets the stage for...

Continue Reading
Pluxee Expands Employee Benefits with Benefício Fácil Acquisition

Updated Category News Views 239

Pluxee Strengthens Its Presence in Brazil Through Strategic Acquisition Pluxee has made a significant move to solidify its operations in Brazil by acquiring 100% of Benefício Fácil, a leading provider of employee mobility benefits. This acquisition marks a pivotal step in reinforcing Pluxee’s position within the dynamic Brazilian market. Details of the Acquisition The...

Continue Reading
Carlyle Credit Income Fund Announces Public Offering Details

Updated Category News Views 312

Carlyle Credit Income Fund Prices New Offering of Preferred Shares In a significant development in the investment community, Carlyle Credit Income Fund (the "Fund") (NYSE: CCIF) has unveiled the details of its latest public offering. The Fund has successfully priced an underwritten public offering for 1.2 million shares of its Series D Preferred Shares, which come with a...

Continue Reading